TrialInternational journal of clinical oncology2018

Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.

Nobuaki Matsubara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.